---
figid: PMC4051134__nihms363783f3
figlink: /pmc/articles/PMC4051134/figure/F3/
number: F3
caption: Functional expression of JAK2 can be blocked at several levels. Deacetylase
  inhibitors (DACi) increase the acetylation and thus inhibit the chaperone function
  of HSP90 (heat shock protein 90). Inhibition of HSP90 leads to a reduction in levels
  of matured JAK2. Specific tyrosine kinase inhibitors prevent activation of downstream
  signaling cascades. Indicated are drugs that are currently in clinical trials for
  the treatment of MPNs. (see also http://cliniclatrials.gov)
pmcid: PMC4051134
papertitle: Targeting JAK2 in the therapy of myeloproliferative neoplasms.
reftext: Mamatha M. Reddy, et al. Expert Opin Ther Targets. ;16(3):313-324.
pmc_ranked_result_index: '107849'
pathway_score: 0.9573541
filename: nihms363783f3.jpg
figtitle: Targeting JAK2 in the therapy of myeloproliferative neoplasms
year: ''
organisms:
- Homo sapiens
ndex: 13189bf2-dedd-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4051134__nihms363783f3.html
  '@type': Dataset
  description: Functional expression of JAK2 can be blocked at several levels. Deacetylase
    inhibitors (DACi) increase the acetylation and thus inhibit the chaperone function
    of HSP90 (heat shock protein 90). Inhibition of HSP90 leads to a reduction in
    levels of matured JAK2. Specific tyrosine kinase inhibitors prevent activation
    of downstream signaling cascades. Indicated are drugs that are currently in clinical
    trials for the treatment of MPNs. (see also http://cliniclatrials.gov)
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ADCY9
  - ADCY8
  - HSP90B1
  - ADCY3
  - ADCY4
  - ADCY7
  - ADCY10
  - JAK2
  - ADCY2
  - ADCY5
  - ADCY6
  - EPO
  - AADAC
  - EPOR
  - HSP90AB1
  - ADCY1
  - TRAP1
  - Lestaurtinib
  - Ruxolitinib
  - AZD1480
  - SB1518
  - LY2784544
genes:
- word: Ac
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY9
  entrez: '115'
- word: Ac
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY8
  entrez: '114'
- word: HSP90
  symbol: HSP90
  source: bioentities_symbol
  hgnc_symbol: HSP90B1
  entrez: '7184'
- word: Ac
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY3
  entrez: '109'
- word: Ac
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY4
  entrez: '196883'
- word: Ac
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY7
  entrez: '113'
- word: Ac
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY10
  entrez: '55811'
- word: Receptor/JAK2
  symbol: JAK2
  source: hgnc_symbol
  hgnc_symbol: JAK2
  entrez: '3717'
- word: Ac
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY2
  entrez: '108'
- word: Ac
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY5
  entrez: '111'
- word: Ac
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY6
  entrez: '112'
- word: EPO
  symbol: EPO
  source: hgnc_symbol
  hgnc_symbol: EPO
  entrez: '2056'
- word: DAC
  symbol: DAC
  source: hgnc_alias_symbol
  hgnc_symbol: AADAC
  entrez: '13'
- word: EPOR
  symbol: EPOR
  source: hgnc_symbol
  hgnc_symbol: EPOR
  entrez: '2057'
- word: HSP90
  symbol: HSP90
  source: bioentities_symbol
  hgnc_symbol: HSP90AB1
  entrez: '3326'
- word: Ac
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY1
  entrez: '107'
- word: HSP90
  symbol: HSP90
  source: bioentities_symbol
  hgnc_symbol: TRAP1
  entrez: '10131'
chemicals:
- word: Lestaurtinib
  source: MESH
  identifier: C119379
- word: Ruxolitinib
  source: MESH
  identifier: C540383
- word: AZD1480
  source: MESH
  identifier: C545606
- word: SB1518
  source: MESH
  identifier: C561234
- word: LY2784544
  source: MESH
  identifier: C581039
diseases: []
figid_alias: PMC4051134__F3
redirect_from: /figures/PMC4051134__F3
figtype: Figure
---
